Maravai LifeSciences Holdings, Inc.
HealthcareNASDAQ:MRVI · NASDAQ Global Select
-$0.23 today
Vol 1.66M · Avg 2.44M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-61.6%
avg 4.0%
ROIC
-0.9%
avg 5.3%
ROA
-17.0%
avg -2.4%
Analysis
ROIC is currently the strongest return metric at -0.9% versus its period average of 5.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Bernd Brust | Chief Executive Officer & Director | $1.29M | — | 59 | $1.65M | 1.14% |
Rajesh J. Asarpota | Executive Vice President & Chief Financial Officer | $850,960.00 | — | 59 | $0.00 | <0.01% |
Rajesh J. Asorpota | Executive Vice President & Chief Financial Officer | $850,960.00 | — | 59 | $0.00 | <0.01% |
Christine Dolan | Executive Vice President & GM of Cygnus Technologies | $803,309.00 | — | 58 | $425,318.00 | 0.29% |
Kurt Oreshack | Executive Vice President, General Counsel & Secretary | $689,912.00 | — | 45 | $335,767.00 | 0.23% |
Robert Andrew Eckert | Chairman of the Board | $175,000.00 | — | 64 | $412,183.00 | 0.28% |
Judith A. Solecki | Senior VP & Chief Human Resources Officer | — | — | — | — | — |
Chad Decker | Senior Vice President of Sales at TriLink & Alphazyme | — | — | — | — | — |
Christopher Benoit | Executive Vice President & Advisor | — | — | — | — | — |
Chanfeng Zhao | Senior Vice President & Chief Scientific Officer | — | — | — | — | — |
Kate E. Broderick | Executive Vice President | — | — | — | $1.81M | 1.25% |
Debra Hart | Senior Director of Investor Relations | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
5
$1.88M
Sells
2
$254,000.00
Net Sentiment
+$1.63M
Net buying
Most Active
Brust Bernd
3 transactions
Analysis
Insiders reported 5 buys worth $1.88M and 2 sells worth $254,000.00 over the last 12 months. That adds up to net buying of $1.63M. Brust Bernd was the most active insider with 3 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +83.4% | -13.2% (8yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | +188.2% | -30.9% (8yr)1 analysts |
Analysis
Recent growth has been strongest in EBIT at +188.2% over three years. Forward estimates point to Revenue at -13.2% (8yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Septerna, Inc.
NASDAQ:SEPN
$1.62B
Tyra Biosciences, Inc.
NASDAQ:TYRA
$1.61B
Iovance Biotherapeutics, Inc.
NASDAQ:IOVA
$1.46B
Vir Biotechnology, Inc.
NASDAQ:VIR
$1.45B
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
$1.19B
Kura Oncology, Inc.
NASDAQ:KURA
$803.41M
Replimune Group, Inc.
NASDAQ:REPL
$733.24M
Ginkgo Bioworks Holdings, Inc.
NYSE:DNA
$515.41M
Prime Medicine, Inc.
NASDAQ:PRME
$501.21M
LENZ Therapeutics, Inc.
NASDAQ:LENZ
$212.27M
Who manages MRVI?
Maravai LifeSciences Holdings, Inc. (MRVI) lists 12 active executives. The top listed executive is Christine Dolan, Executive Vice President & GM of Cygnus Technologies.
Are MRVI insiders buying or selling?
Recent insider activity shows net selling of $75.34M.
Explore More
Continue the stock analysis
Jump to another research area for this company.